ICER Plans Report on Acute Migraine Treatments

from tHEORetically Speaking: The HealthEconomics.Com Blog at on June 28, 2019 at 02:32PM

The Institute for Clinical and Economic Review (ICER) released a new report outlining a planned review of acute migraine treatments.

According to a press release, ICER is planning to assess the following treatments:

  • Biohaven’s rimegepant;
  • Allergan’s ubrogepant; and
  • Eli Lilly’s agonist lasmiditan.

ICER is accepting comments on the draft scoping document. The deadline to submit feedback is 5 p.m. July 19.

An updated scoping document will be released around July 29.

To read the full press release, click here.

Click here to read the draft scoping document.